Fig. 11
From: Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome
Effect of acute single-dose RBAC on auditory chirp in FXS participants. For left (upper row) and right (lower row) hemispheres, and for baclofen (left 3 columns) and placebo (right 3 columns) the left panel shows the averaged inter-trial phase coherence (ITPC or phase locking factor) before treatment (Pre), the middle panel shows the averaged ITPC after treatment (Post) and the right panel shows Post–Pre. Red areas in the right panels (Post–Pre) represent positive ITPC differences and blue areas represent negative ITPC differences